Obesity Clinical Trials in Louisville, Kentucky

13 studies are recruiting for obesity in Louisville, Kentucky right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

   Obesity is a condition where a person has excessive body fat, defined by a body mass index (BMI) of 30 kg/m2 or higher. The goal of this study is to evaluate the effect of various doses of ABBV-295 compared to placebo on reducing body weight at Week 32 in participants with obesity or overweight wit…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   L-MARC Research Center /ID# 282008, Louisville, Kentucky

   Locations

   64 in total

   Run by

   AbbVie

   See if you can join NCT07752979 on ClinicalTrials.gov

2. A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity

   The purpose of this study is to learn about the safety and effectiveness of berobenatide in adults with overweight or obesity who have already lost weight while taking semaglutide or tirzepatide. The study does not include people with diabetes. Participants will be in the study for about 11 months.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Monroe Biomedical Research, Louisville, Kentucky

   Locations

   16 in total

   Run by

   Pfizer

   See if you can join NCT07845500 on ClinicalTrials.gov

3. A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

   The purpose of this clinical study is to learn about the effects and safety of berobenatide (PF-08653944). This may help people with overweight or obesity lose weight. People in this study may also have type 2 diabetes. About 950 adults will be in this study. Berobenatide will be compared to a plac…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Monroe Biomedical Research, Louisville, Kentucky

   Locations

   72 in total

   Run by

   Pfizer

   See if you can join NCT07595549 on ClinicalTrials.gov

4. Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)

   The main purpose of this study, performed under Master Protocol J4M-MC-PWMP (NCT06672549), is to evaluate the efficacy, safety, and pharmacokinetics of tirzepatide as an addition to healthy lifestyle in participants 6 to less than 12 years of age, with obesity. Participation in the study will last …

   Stage

   Phase 3

   Ages

   6 to 11

   Site

   Norton Children's Endocrinology, Louisville, Kentucky

   Locations

   82 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07817875 on ClinicalTrials.gov

5. A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

   The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will …

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Monroe Biomedical Research - Louisville, Louisville, Kentucky

   Locations

   40 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07589608 on ClinicalTrials.gov

6. A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

   The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newl…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Monroe Biomedical Research - Louisville, Louisville, Kentucky

   Locations

   57 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06143956 on ClinicalTrials.gov

7. A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

   The purpose of this pediatric, chronic weight management, Phase 3 Master Protocol (PWMP) is to create a framework to evaluate the safety and efficacy of pharmacologic agents for the treatment of obesity or overweight in pediatric participants.

   Stage

   Phase 3

   Ages

   6 to 17

   Site

   Norton Children's Endocrinology, Louisville, Kentucky

   Locations

   116 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06672549 on ClinicalTrials.gov

8. Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

   The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity or overweight. Trial 20250197 is an extension of trial 20210181 (NCT06858839).

   Stage

   Phase 3

   Ages

   18 to 99

   Site

   Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky

   Locations

   92 in total

   Run by

   Amgen

   See if you can join NCT07684235 on ClinicalTrials.gov

9. Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

   The purpose of this study is to see how oral semaglutide, when taken in lower doses help lowering of body weight in participants with excess body weight when compared to 'dummy' tablets (placebo). Results from this study will help select the most optimal lower dose of oral semaglutide that can be u…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   L-MARC Research Center, Louisville, Kentucky

   Locations

   62 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07770841 on ClinicalTrials.gov

10. A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

    This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to f…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    UofL Health Care Outpatient, Louisville, Kentucky

    Locations

    838 in total

    Run by

    Novo Nordisk A/S

    See if you can join NCT07567001 on ClinicalTrials.gov

11. AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

    This study is being done to look at the safety and effect of NNC0487-0111 in people with excess body weight and knee osteoarthritis when compared to placebo. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111, (the tr…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Monroe Biomedical Research, LLC, Louisville, Kentucky

    Locations

    81 in total

    Run by

    Novo Nordisk A/S

    See if you can join NCT07509307 on ClinicalTrials.gov

12. Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

    Study GSBR-1290-12 is a Phase 3 pivotal, multicenter, global, randomized, placebo-controlled, double-blind study to investigate the long-term efficacy, safety, and tolerability of 3 maintenance doses of aleniglipron once daily (QD) compared with placebo, when used in combination with a reduced-calo…

    Stage

    Phase 3

    Ages

    18 to 79

    Site

    ACCOMPLISH-1 Research Site, Louisville, Kentucky

    Locations

    71 in total

    Run by

    Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

    See if you can join NCT07654361 on ClinicalTrials.gov

13. Adrenergic Cholinergic Enteric Measures/Mapping

    Patients seen who had autonomic and enteric profiling (Adrenergic, Cholinergic, Enteric Measures/Mapping=ACEM_ from 2012-2019 at the University of Louisville.

    Stage

    Not phased

    Ages

    10 to 80

    Site

    University of Louisville, Louisville, Kentucky

    Run by

    University of Louisville

    See if you can join NCT04013282 on ClinicalTrials.gov